Analyst Ryan MacDonald from Needham maintained a Buy rating on Phreesia (PHR – Research Report) and keeping the price target at $29.00.Stay ...

Citi raised the firm’s price target on Phreesia (PHR) to $35 from $31 and keeps a Buy rating on the shares as part of a 2025 outcook for the ...

The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $31.0, a high ...

Phreesia (NYSE:PHR – Get Free Report) had its target price raised by investment analysts at KeyCorp from $28.00 to $30.00 in a note issued to investors on Wednesday,Benzinga reports. The brokerage ...

Fintel reports that on January 8, 2025, RBC Capital upgraded their outlook for Phreesia (NYSE:PHR) from Sector Perform to ...

Analyst predicts Phreesia's revenue per client will accelerate, as company shifts focus to monetizing existing clients.

From a technical perspective, Phreesia, Inc. (PHR) is looking like an interesting pick, as it just reached a key level of support. PHR's 50-day simple moving average crossed above its 200-day simple ...

Phreesia’s Q3 earnings show solid revenue growth, but customer growth is decelerating, impacting overall performance. Fiscal 2025 guidance improved with higher EBITDA and tighter revenue ...

One class action was filed against Deloitte Consulting and seven were filed against health care software company Phreesia and ...

76.5% of OptimizeRx shares are owned by institutional investors. Comparatively, 92.1% of Phreesia shares are owned by institutional investors. 6.1% of OptimizeRx shares are owned by insiders.

Phreesia jumps 6% to $22.83 after Q3 results, updated guidance Phreesia narrows FY25 revenue view to $418M-$420M, consensus $419.1M Phreesia guides initial FY26 revenue $472M-$482M, consensus $480.5M ...